Anas Younes

42.5k citations

529 papers · 22.1k indexed · 4 hit papers · h-index 77

Impact in

Pathology and Forensic Medicine top 0.01%
- Lymphoma Diagnosis and Treatment
Genetics top 0.05%
- Chronic Lymphocytic Leukemia Research

Papers in

Pathology and Forensic Medicine 376
- Lymphoma Diagnosis and Treatment 366
Genetics 166
- Chronic Lymphocytic Leukemia Research 164

Co-authors: Jorge Romaguera Fernando Cabanillas Peter McLaughlin Andres Forero‐Torres Nancy L. Bartlett Eric L. Sievers Dana A. Kennedy Georgios Georgakis
Journals: Blood (182 papers)Journal of Clinical Oncology (61 papers)British Journal of Haematology (35 papers)Cancer (16 papers)Annals of Oncology (12 papers)
Partner nations: United States Canada Italy

In The Last Decade

Anas Younes

523 papers receiving 21.7k citations

Hit Papers

align trajectories log scale

Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial 2018 · 455 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2018 Journal of Clinical Oncology
2016 Journal of Molecular Diagnostics
2012 Journal of Clinical Oncology
2010 New England Journal of Medicine

Peers

Countries citing papers authored by Anas Younes

Since Specialization

Citations

This map shows the geographic impact of Anas Younes's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anas Younes with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anas Younes more than expected).

Fields of papers citing papers by Anas Younes

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anas Younes. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anas Younes. The network helps show where Anas Younes may publish in the future.

Co-authors

The 25 scholars most cited alongside Anas Younes, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Anas Younes Line = papers co-authored together Anas Younes links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	SETD1B mutations confer apoptosis resistance and BCL2 independence in B cell lymphoma The Journal of Experimental Medicine ·Ana Portelinha, Shenqiu Wang, S. Parsa, Man Jiang, Alexander N. Gorelick, Sagarajit Mohanty, Soumya Sharma, Elisa de Stanchina, Marjan Berishaj, Chunying Zhao, James A. Heward, Neeraj K. Aryal, Omid Tavana, Jiayu Wen, Jude Fitzgibbon, Ahmet Doǧan, Anas Younes, Ari Melnick, Hans-Guido Wendel	2024	5
2	Outsourcing Hospitality: Power, Responsibility, and Inequality in Community Sponsorship Journal of International Migration and Integration / Revue de l integration et de la migration internationale ·Karen Smith, Anas Younes, Zuhair Fakir, Carol Ballantine	2024	1
3	A comparison of the prognostic performance of the Lugano 2014 and RECIL 2017 response criteria in patients with NHL from the phase III GOYA and GALLIUM trials SHILAP Revista de lepidopterología ·Lale Kostakoğlu, Maurizio Martelli, Laurie H. Sehn, Andrew Davies, Marek Trněný, Michael Herold, Umberto Vitolo, Wolfgang Hiddemann, Judith Trotman, Andrea Knapp, Federico Mattiello, Tina Nielsen, Deniz Şahin, Gila Sellam, Carol Ward, Anas Younes	2023	1
4	Synthetic lethality of drug-induced polyploidy and BCL-2 inhibition in lymphoma Nature Communications ·Ana Portelinha, Mariana Da Silva Ferreira, Tatiana Erazo, Man Jiang, Zahra Asgari, Elisa de Stanchina, Anas Younes, Hans‐Guido Wendel	2023	7
5	Bendamustine in combination with ofatumumab as first line treatment for elderly patients with mantle cell lymphoma: a phase II risk-adapted design Leukemia & lymphoma ·Anita Kumar, Carla Casulo, Erel Joffe, Craig H. Moskowitz, John F. Gerecitano, Alison J. Moskowitz, Anas Younes, Pamela Drullinsky, Esther Drill, Morgan Choma, Clare Grieve, Ashlee Joseph, Leana Laraque, Dylan L. Schick, Andrew D. Zelenetz, Paul A. Hamlin	2022	1
6	Brentuximab Vedotin plus Chemotherapy in North American Subjects with Newly Diagnosed Stage III or IV Hodgkin Lymphoma Clinical Cancer Research ·Radhakrishnan Ramchandren, Ranjana H. Advani, Stephen M. Ansell, Nancy L. Bartlett, Robert Chen, Joseph M. Connors, Tatyana Feldman, Andres Forero‐Torres, Jonathan W. Friedberg, Ajay K. Gopal, Leo I. Gordon, John Kuruvilla, Kerry J. Savage, Anas Younes, Gerald Engley, Thomas Manley, Keenan Fenton, David J. Straus	2019	30
7	Safety and Efficacy of Atezolizumab in Combination with Rituximab Plus CHOP in Previously Untreated Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Updated Analysis of a Phase I/II Study Blood ·Anas Younes, John M. Burke, Bruce D. Cheson, Catherine Diefenbach, Silvia Ferrari, Uwe Hahn, Eliza A. Hawkes, Cyrus Khan, Izidore S. Lossos, Gerardo Musuraca, Monica Tani, Umberto Vitolo, Sam Yuen, Aparna Raval, Mahesh Shivhare, Tina Nielsen, Gila Sellam, Jeff P. Sharman	2019	20
8	Active surveillance for nodular lymphocyte-predominant Hodgkin lymphoma Blood ·Sven Borchmann, Erel Joffe, Craig H. Moskowitz, Andrew D. Zelenetz, Ariela Noy, Carol S. Portlock, John F. Gerecitano, Connie Lee Batlevi, Philip Caron, Pamela Drullinsky, Audrey Hamilton, Paul A. Hamlin, Steven M. Horwitz, Anita Kumar, Matthew J. Matasar, Alison J. Moskowitz, Colette Owens, M. Lia Palomba, Anas Younes, David J. Straus	2019	26
9	Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial Journal of Clinical Oncology ·Philippe Armand, Andreas Engert, Anas Younes, Michelle A. Fanale, Armando Santoro, Pier Luigi Zinzani, John M. Timmerman, Graham P. Collins, Radhakrishnan Ramchandren, Jonathon B. Cohen, Jan Paul de Boer, John Kuruvilla, Kerry J. Savage, Marek Trněný, Margaret A. Shipp, Kazunobu Kato, Anne Sumbul, Benedetto Farsaci, Stephen M. Ansell Hit paper breakdown →	2018	455
10	Natural History of Hypogammaglobulinemia in Patients with Follicular Lymphoma and the Impact of Anti-CD20-Based Therapy Blood ·Thaís Fischer, Ai Ni, Jacob D. Soumerai, Anna Alperovich, Connie Lee Batlevi, Anas Younes, Andrew D. Zelenetz	2017	2
11	Characterization of a c-Rel Inhibitor That Mediates Anticancer Properties in Hematologic Malignancies by Blocking NF-κB–Controlled Oxidative Stress Responses Cancer Research ·Yusuke Shono, Andrea Z. Tuckett, Hsiou‐Chi Liou, Ekaterina Doubrovina, Enrico Derenzini, Samedy Ouk, Jennifer J. Tsai, Odette M. Smith, Emily R. Levy, Fabiana M. Kreines, Carly G.K. Ziegler, Mary I. Scallion, Mikhail Doubrovin, Glenn Heller, Anas Younes, Richard J. O’Reilly, Marcel R.M. van den Brink, Johannes L. Zakrzewski	2016	33
12	Phase II study of an AKT inhibitor MK2206 in patients with relapsed or refractory lymphoma British Journal of Haematology ·Yasuhiro Oki, Michelle A. Fanale, Jorge Romaguera, Luis Fayad, Nathan Fowler, Amanda Copeland, Felipe Samaniego, Larry W. Kwak, Sattva S. Neelapu, Michael Wang, Lei Feng, Anas Younes	2015	68
13	Brentuximab Vedotin Combined with ABVD or AVD for Patients with Newly Diagnosed Advanced Stage Hodgkin Lymphoma: Long Term Outcomes Blood ·Joseph M. Connors, Stephen Ansell, Steven I. Park, Michelle A. Fanale, Anas Younes	2014	10
14	Long term results of a phase 2 study of vincristine sulfate liposome injection ( M arqibo ^® ) substituted for non‐liposomal vincristine in cyclophosphamide, doxorubicin, vincristine, prednisone with or without rituximab for patients with untreated aggressive non‐ H odgkin lymphomas British Journal of Haematology ·Fredrick B. Hagemeister, Maria Alma Rodriguez, Steven R. Deitcher, Anas Younes, Luis Fayad, André Goy, Nam H. Dang, Arthur Forman, Peter McLaughlin, Leonard Jeffrey Medeiros, Barbara Pro, Jorge Romaguera, Felipe Samaniego, Jeffrey A. Silverman, Andreas H. Sarris, Fernando Cabanillas	2013	24
15	Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma Journal of Clinical Oncology ·Anas Younes, Ajay K. Gopal, Scott E. Smith, Stephen M. Ansell, Joseph D. Rosenblatt, Kerry J. Savage, Radhakrishnan Ramchandren, Nancy L. Bartlett, Bruce D. Cheson, Sven de Vos, Andres Forero‐Torres, Craig H. Moskowitz, Joseph M. Connors, Andreas Engert, Emily K. Larsen, Dana A. Kennedy, Eric L. Sievers, Robert Chen Hit paper breakdown →	2012	1014
16	Brentuximab Vedotin in Transplant-Naïve Patients with Relapsed or Refractory Hodgkin Lymphoma: Analysis of Two Phase I Studies The Oncologist ·Andres Forero‐Torres, Michelle A. Fanale, Ranjana H. Advani, Nancy L. Bartlett, Joseph D. Rosenblatt, Dana A. Kennedy, Anas Younes	2012	34
17	Improving T-cell Therapy for Relapsed EBV-Negative Hodgkin Lymphoma by Targeting Upregulated MAGE-A4 Clinical Cancer Research ·Carolina Colli Cruz, Ulrike Gerdemann, Ann M. Leen, Jessica A. Shafer, Stephanie Ku, Benjamin Tzou, Terzah M. Horton, Andrea M. Sheehan, Amanda Copeland, Anas Younes, Cliona M. Rooney, Helen E. Heslop, Catherine M. Bollard	2011	56
18	Phase II Study of Yttrium-90–Ibritumomab Tiuxetan in Patients With Relapsed or Refractory Mantle Cell Lymphoma Journal of Clinical Oncology ·Michael Wang, Yasuhiro Oki, Barbara Pro, Jorge Romaguera, Maria Alma Rodriguez, Felipe Samaniego, Peter McLaughlin, Frederick Hagemeister, Sattva S. Neelapu, Amanda Copeland, Barry I. Samuels, Evelyne M. Loyer, Yuan Ji, Anas Younes	2009	66
19	Vorinostat inhibits STAT6-mediated TH2 cytokine and TARC production and induces cell death in Hodgkin lymphoma cell lines Blood ·Daniela Buglio, Georgios Georgakis, Shino Hanabuchi, Kazuhiko Arima, Noor M. Khaskhely, Yong-Jun Liu, Anas Younes	2008	133
20	Randomized comparison of frontline alternating chemotherapy versus brief induction followed by autologous stem cell transplant for aggressive lymphomas Blood ·Maria Alma Rodriguez, Koen van Besien, Fredrick B. Hagemeister, Sergio Giralt, Peter McLaughlin, James Gajewski, Jorge Romaguera, Issa F. Khouri, Anas Younes, Fernando Cabanillas, Richard E. Champlin	2003	2

About Anas Younes

Anas Younes is a scholar working on Pathology and Forensic Medicine, Genetics, Oncology, Hematology and Immunology, having authored 529 papers that have together received 22.1k indexed citations. Recurring topics across this work include Lymphoma Diagnosis and Treatment (366 papers), Chronic Lymphocytic Leukemia Research (164 papers), Viral-associated cancers and disorders (78 papers), CNS Lymphoma Diagnosis and Treatment (55 papers), Histone Deacetylase Inhibitors Research (51 papers), CAR-T cell therapy research (51 papers), Lung Cancer Treatments and Mutations (46 papers) and Monoclonal and Polyclonal Antibodies Research (42 papers). The work is most often cited by research in Pathology and Forensic Medicine (11.6k citations), Genetics (5.0k citations), Oncology (10.9k citations), Immunology (4.0k citations) and Neurology (2.6k citations). Anas Younes has collaborated with scholars based in United States, Canada and Italy. Frequent co-authors include Jorge Romaguera, Fernando Cabanillas, Peter McLaughlin, Andres Forero‐Torres, Nancy L. Bartlett, Eric L. Sievers, Dana A. Kennedy, Georgios Georgakis, Barbara Pro and Luis Fayad. Their work appears in journals such as Blood, Journal of Clinical Oncology, British Journal of Haematology, Cancer and Annals of Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact